Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism

Journal of Diabetes Investigation

Volumn 2, Issue 4, 2011, Pages 318-323

  Asai, Akira ^a   Nakagawa, Kiyotaka ^b   Higuchi, Ohki ^c   Kimura, Toshiyuki ^d   Kojima, Yoshihiro ^e   Kariya, Jun ^c   Miyazawa, Teruo ^b   Oikawa, Shinichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Project M Co Ltd   (Japan)

^d NATIONAL AGRICULTURAL RESEARCH CENTER FOR TOHOKU REGION   (Japan)

^e Minato Pharmaceutical Co Ltd   (Japan)

Author keywords

Glucosidase inhibitor; 1 deoxynojirimycin; Postprandial hyperglycemia

Indexed keywords

1 DEOXYNOJIRIMYCIN; 1,5 ANHYDROSORBITOL; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; MULBERRY EXTRACT; PLACEBO;

ADULT; ARTICLE; CARBOHYDRATE TOLERANCE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISORDERS OF CARBOHYDRATE METABOLISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULBERRY; PATIENT COMPLIANCE; PLANT LEAF; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84871712115     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00101.x     Document Type: Article

References (29)

1. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia 2001; 44: 2107-2114.
2. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7.
3. Bazzano LA, Serdula M, Liu S. Prevention of type 2 diabetes by diet and lifestyle modification. J Am Coll Nutr 2005; 24: 310-319.
4. Padwal R, Majumdar SR, Johnson JA, et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005; 28: 736-744.
5. Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab 2007; 33: 3-12.
6. Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-1614.
7. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490.
8. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376: 103-111.
9. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
10. The NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-1476.
11. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
12. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.
13. Asano N, Yamashita T, Yasuda K, et al. Polyhydroxylated alkaloids isolated from mulberry trees (Morus alba L.) and silkworms (Bombyx mori L.). J Agric Food Chem 2001; 49: 4208-4213.
14. Asano N. Glycosidase inhibitors: update and perspectives on practical use. Glycobiology 2003; 13: 93R-104R.
15. Miyahara C, Miyazawa M, Satoh S, et al. Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats. J Nutr Sci Vitaminol 2004; 50: 161-164.
16. Asano N. Sugar-mimicking glycosidase inhibitors: bioactivity and application. Cell Mol Life Sci 2009; 66: 1479-1492.
17. Kimura T, Nakagawa K, Saito Y, et al. Determination of 1-deoxynojirimycin in mulberry leaves using hydrophilic interaction chromatography with evaporative light scattering detection. J Agric Food Chem 2004; 52: 1415-1418.
18. Kimura T, Nakagawa K, Kubota H, et al. Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. J Agric Food Chem 2007; 55: 5869-5874.
19. Seino Y, Nanjo K, Tajima N, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Japan Diab Soc 2010; 53: 450-467 (Japanese).
20. Zhong L, Furne JK, Levitt MD. An extract of black, green, and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers. Am J Clin Nutr 2006; 84: 551-555.
21. Mudra M, Ercan-Fang N, Zhong L, et al. Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects. Diabetes Care 2007; 30: 1272-1274.
22. Akanuma Y, Morita M, Fukuzawa N, et al. Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients. Diabetologia 1988; 31: 831-835.
23. Yamanouchi T, Akaoka I, Akanuma Y, et al. Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents. Am J Physiol 1990; 258: E423-E427.
24. Yamanouchi T, Moromizato H, Shinohara T, et al. Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism 1992; 41: 862-867.
25. Yamanouchi T, Ogata N, Tagaya T, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 1996; 347: 1514-1518.
26. Dungan KM, Buse JB, Largay J, et al. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29: 1214-1219.
27. van de Laar FA, Lucassen PL, Akkermans RP, et al. a-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163.
28. Jew S, Vanstone CA, Antoine JM, et al. Generic and productspecific health claim processes for functional foods across global jurisdictions. J Nutr 2008; 138: 1228S-1236S.
29. Yamada K, Sato-Mito N, Nagata J, et al. Health claim evidence requirements in Japan. J Nutr 2008; 138: 1192S-1198S.